10-K: CONMED Corporation Reports Increased Net Sales in 2024 Annual Report

CONMED Corporation's 2024 annual report reveals a 5.0% increase in net sales, driven by growth in both orthopedic and general surgery product lines.

Summary

• CONMED Corporation's Form 10-K for the fiscal year ended December 31, 2024, includes forward-looking statements subject to various risks and uncertainties.
• The company was incorporated in New York in 1970 and became a Delaware corporation in May 2020.
• CONMED is a medical technology company providing devices and equipment for surgical procedures, with 3,900 employees and headquarters in Largo, Florida.
• The company's business strategy focuses on new product introductions, strategic acquisitions, manufacturing efficiencies, geographic diversification, and active participation in the medical community.
• In 2024, orthopedic surgery accounted for 42% of net sales and general surgery accounted for 58%.
• Net sales increased 5.0% to $1,307.0 million in 2024, with orthopedic surgery up 2.0% and general surgery up 7.2%.
• Approximately 85% of CONMED's revenues are derived from single-use products.
• The company faces risks related to economic conditions, public health crises, Ethylene Oxide sterilization, regulatory compliance, competition, and indebtedness.
• CONMED's Board of Directors may limit or discontinue dividend payments in the future.
• The company's international operations are subject to foreign currency fluctuations and other risks associated with operating in countries outside the United States.
• The company's cybersecurity measures include leveraging the NIST framework, employing technologies and consultants, and conducting employee training.
• Net cash provided by operating activities was $167.0 million in 2024, compared to $125.3 million in 2023.
• As of December 31, 2024, CONMED had $914.6 million of debt outstanding.
• The Board of Directors has authorized a $200.0 million share repurchase program, with $37.4 million remaining available as of December 31, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with increased net sales and improved gross profit margins. However, it also acknowledges ongoing challenges related to inflation, supply chain disruptions, and potential regulatory issues, resulting in a moderately positive sentiment score.

Positives

• Net sales increased by 5.0% in 2024, indicating growth in the company's core business segments.
• Gross profit margins improved, reflecting better product mix and the absence of inventory step-up costs from the In2Bones acquisition.
• Selling and administrative expenses decreased as a percentage of net sales, driven by lower costs related to contingent consideration adjustments and warehouse management system implementation.
• Net cash provided by operating activities increased, driven by higher net income.
• The company is actively managing cybersecurity risks and investing in protective measures.
• The company is committed to pay equity for all employees and conducts an annual review of pay equity globally.

Negatives

• The company is experiencing higher manufacturing and operating costs due to inflationary pressures and ongoing supply chain challenges.
• The company faces potential issues with certain royalty payments to surgeons involved in design teams, which are under review by the U.S. Department of Justice.
• The company is subject to risks related to public health crises, which could adversely affect its business, financial condition, or results of operations.
• The company is subject to limitations on the availability of Ethylene Oxide (EtO) sterilization services, which may limit its ability to sell certain sterile products.
• The company is subject to risks related to its indebtedness, including restrictions on its ability to incur additional debt, pay dividends, and pursue acquisitions.

Risks

• The company's financial performance is dependent on conditions in the healthcare industry and the broader economy, and a potential economic downturn could adversely affect its business.
• The company faces risks related to compliance with domestic and foreign laws and regulations, including the Foreign Corrupt Practices Act.
• The company's products are subject to product recall, and regulatory issues could have a material adverse effect on its business, financial condition, or results of operations.
• The company operates in a highly competitive market, and competitive pricing pressures or the introduction of new products by competitors could have an adverse effect on its revenues.
• The company's results and operations could be adversely affected by raw material shortages, inflation, price increases, economic or geopolitical developments, including protectionist trade policies such as tariffs, or other events.
• The company may not be able to keep pace with technological change or to successfully develop new products with wide market acceptance, which could cause it to lose business to competitors.
• The terms of the company's indebtedness may restrict its current and future operations, particularly its ability to respond to changes or to take certain actions.
• The company could experience a failure of a key information technology system, process or site or a breach of information security, including a cybersecurity breach or failure of one or more key information technology systems, networks, processes, associated sites or service providers, and could potentially become liable for a breach of various data privacy regulations.
• The company relies on a third party to obtain, process and distribute sports medicine allograft tissue. If such tissue cannot be obtained, is not accepted by the market or is not accepted under numerous government regulations, our results of operations could be negatively impacted.
• The company's significant international operations subject it to foreign currency fluctuations and other risks associated with operating in countries outside the United States.
• Violations of environmental, social and governance laws and regulations and climate change initiatives could materially and adversely affect our business, financial condition, and results of operations.

Future Outlook

The company expects to be impacted by the macro-economic environment and is experiencing higher manufacturing and operating costs caused by inflationary pressures and ongoing supply chain challenges, which are expected to continue in 2025. Management believes that cash flow from operations, including cash and cash equivalents on hand and available borrowing capacity under our seventh amended and restated senior credit agreement, will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital expenditures, dividend payments and common stock repurchases in the foreseeable future. We expect an increased level of capital spending during the year ending December 31, 2025 compared to 2024.

Management Comments

• Management believes that the allowance for doubtful accounts is adequate to provide for probable losses resulting from accounts receivable.
• Management believes that cash flow from operations, including cash and cash equivalents on hand and available borrowing capacity under our seventh amended and restated senior credit agreement, will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital expenditures, dividend payments and common stock repurchases in the foreseeable future.
• Management believes we could access capital markets, as necessary, to fund future business acquisitions.

Industry Context

CONMED competes in the orthopedic and general surgery medical device markets against companies ranging from large manufacturers with multiple business units to smaller manufacturers with limited product offerings. The company believes it has appropriate product offerings and adequate market share to compete effectively in these markets. The global markets are constantly changing due to technological advances.

Comparison to Industry Standards

• CONMED competes with major players like Smith & Nephew, Arthrex, Stryker, Johnson & Johnson (DePuy Mitek), Zimmer Biomet, Paragon 28, and Treace Medical Concepts in the orthopedic surgery market.
• In powered instruments, CONMED competes with Stryker, Medtronic, Johnson & Johnson (DePuy Synthes), and Zimmer Biomet.
• In general surgery, CONMED's competitors include Medtronic, Johnson & Johnson (Ethicon Endo-Surgery), Stryker Endoscopy, Olympus, ERBE Elektromedizin GmbH, and Applied Medical Resources Corporation.
• In advanced endoscopic technologies, CONMED competes with Boston Scientific, Cook Medical, Merit Medical Endotek, Olympus, STERIS Corporation (U.S. Endoscopy), Cantel MedicalMedivators, Inc., Cardinal Health Inc., and 3M Company.

Legal Proceedings

• The company voluntarily informed the U.S. Department of Justice (DOJ) of potential issues with certain royalty payments related to surgeons involved in design teams and is fully cooperating with the DOJ's review of the matter.
• CONMED had been defending two Georgia State Court actions. The first action was filed in May 2020 in Cobb County by various current and former employees, contract workers and others against CONMED and a contract sterilizer (the Cobb County Action). All claims against CONMED in the Cobb County Action have now been dismissed, however, CONMED is indemnifying its sterilization provider who remains in the case.
• The second action was filed in April 2021 in Douglas County against CONMEDs current and former landlord and property managers (the Douglas County Action). Plaintiffs alleged the same injuries as in the Cobb County Action. In July 2024, CONMED reached an agreement to settle this matter for an amount covered by CONMEDs insurance, and this litigation was dismissed in November 2024.
• CONMED litigated two lawsuits against Chubb relative to its coverage of these claims: one involving CONMEDs claim for coverage for the indemnification claims arising from the Cobb County Action, and the other concerning CONMEDs claim for coverage for the indemnification claims arising from the Douglas County Action.
• The government of Italy passed a law in late 2015 to tax medical device companies on revenue derived from sales to public hospitals. The Company challenged the imposition of the medical device tax in Italy, as did many other medical device companies, on the grounds that the law was never implemented properly with regulations. On July 22, 2024, the Italian Constitutional Court determined the tax to be constitutional, however, a 52% discount on amounts due for the years 2015-2018 was granted as part of the ruling.

Stakeholder Impact

• Shareholders: The company's increased net sales and improved profitability could lead to higher stock prices and dividend payments.
• Employees: The company's commitment to pay equity and talent management practices could improve employee morale and retention.
• Customers: The company's focus on new product introductions and product enhancements could provide customers with innovative surgical solutions.
• Suppliers: The company's strategic partnerships with key suppliers could lead to more stable and reliable supply chains.
• Creditors: The company's strong cash flow and compliance with debt covenants could improve its creditworthiness.

Next Steps

• The company will continue to monitor and adjust its business strategy in response to the conflicts in Ukraine and the Middle East.
• The company will continue to monitor its spending and expenses in light of the macro-economic environment.
• The company will continue to invest in IT Security to improve technical capabilities, streamline response effectiveness, and harden preventive, detection, and response measures, while growing the core security organization to support business growth efforts.

Key Dates

Keywords

CONMED, medical devices, surgical procedures, orthopedic surgery, general surgery, net sales, acquisitions, risk factors, financial performance, Ethylene Oxide, cybersecurity, indebtedness, allograft tissue, international operations, ESG